CoChat
Sign Up
Cited by 88

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis

Alvarez, M. Lucrecia, Khosroheidari, Mahdieh, Eddy, Elena, Done, Stefania C.·2015·Atherosclerosis
DOI 10.1016/j.atherosclerosis.2015.08.023PMC PMC4575910
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.atherosclerosis.2015.08.023

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Numerous miRNAs directly bind LDLR mRNA 3′UTR and decrease its expression, including miR-27a, miR-27b, miR-128-1, miR-128-3p, miR-130b, miR-148a, miR-184a, miR-185, and miR-301b.

    “Numerous miRNAs have been shown to directly bind LDLR mRNA 3' UTR and decrease its expression (Fig. 2), including miR-27a, miR-27b, miR-128-1, miR-128-3p, miR-130b, miR-148a, miR-184a, miR-185, and miR-301b [43][44][45][46][47][48].”

    From The low-density lipoprotein receptor: Emerging post-transcriptional regulatory mechanisms (2025) · cites this paper as [43]

    The Results section ('miR-27a directly downregulates LDLR by binding to its 3′UTR region') confirms direct binding and reduced LDLR expression for miR-27a. This paper does not establish that the other listed miRNAs directly bind the LDLR 3′UTR and decrease its expression; the Discussion instead notes evidence suggesting miR-27b does not modulate LDLR in differentiated hepatocyte-like cells. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • miR-27a, miR-27b, miR-128-1, miR-128-3p, miR-130b, miR-148a, miR-184a, miR-185, and miR-301b inhibit expression of the LDLR, decreasing LDLR.

    “miR-27a, miR-27b, miR-128-1, miR-128-3p, miR-130b, miR-148a, miR-184a, miR-185, miR-301b Inhibit expression of the LDLR ↓ [43-48]”

    From The low-density lipoprotein receptor: Emerging post-transcriptional regulatory mechanisms (2025) · cites this paper as [43]

    The Results section shows that miR-27a decreases LDLR mRNA and protein in HepG2 cells. The cited paper does not establish the same LDLR effect for the other listed miRNAs; its Discussion says prior findings suggest miR-27a, but not miR-27b, modulates LDLR in differentiated hepatocyte-like cells. The citation therefore supports the miR-27a part of the grouped claim, not the full list. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • Overexpression of miR-27a decreased LDLR expression by 50% in HepG2 cells.

    “Conversely, overexpression of miR-27a decreased LDLR expression by 50% in HepG2 cells55.”

    From Pathways and Molecular Mechanisms Governing LDL Receptor Regulation (2025) · cites this paper as [55]

    The Abstract (Methods and Results; page not provided) reports that miR-27a decreased LDLR levels by 40% in HepG2 cells. The Results section reports an approximately 50% decrease in LDLR activity, not expression, after miR-27a mimic transfection. The claim conflates those two measurements. (LLM, conf=0.90)

    Experimental — accuracy not yet measured

  • LDLR mRNA contains one well conserved miR-27a binding site.

    “LDLR mRNA contains one well conserved miR-27a binding site55.”

    From Pathways and Molecular Mechanisms Governing LDL Receptor Regulation (2025) · cites this paper as [55]

  • miR-27a and miR-27b are two highly similar miRNAs originating from the same seed sequence with a difference of a single nucleotide.

    “The miR-27 family (miR-27a and miR-27b) are two highly similar miRNAs originating from the same seed sequence with a difference of a single nucleotide55.”

    From Pathways and Molecular Mechanisms Governing LDL Receptor Regulation (2025) · cites this paper as [55]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 43

  1. Contu, 2010, Circulating microRNAs as potential biomarkers of coronary artery disease: a promise to be fulfilled?, Circ. Res., 107, 573, 10.1161/CIRCRESAHA.110.227983 · DOI
  2. Go, 2012, Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis, Yale J. Biol. Med., 85, 19
  3. Mozaffarian, 2015, Heart disease and stroke statistics–2015 update: a report from the American Heart Association, Circulation, 131, e29, 10.1161/CIR.0000000000000152 · DOI · Paper page
  4. Goldstein, 2009, The LDL receptor, Arterioscler. Thromb. Vasc. Biol., 29, 431, 10.1161/ATVBAHA.108.179564 · DOI · Paper page
  5. Abifadel, 2003, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat. Genet., 34, 154, 10.1038/ng1161 · DOI · Paper page
  6. Ye, 2012, LRP6 protein regulates low density lipoprotein (LDL) receptor-mediated LDL uptake, J. Biol. Chem., 287, 1335, 10.1074/jbc.M111.295287 · DOI · Paper page
  7. Kidd, 2006, Life after statin patent expiries, Nat. Rev. Drug Discov., 10, 813, 10.1038/nrd2156 · DOI
  8. Dong, 2010, Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters, J. Lipid Res., 51, 1486, 10.1194/jlr.M003566 · DOI
  9. Athyros, 2015, High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus, J. Diabetes Complicat., 29, 142, 10.1016/j.jdiacomp.2014.10.004 · DOI
  10. Hegland, 2010, The effect of statin therapy on the progression of carotid artery stenosis in relation to stenosis severity, Acta Neurol. Scand., 121, 11, 10.1111/j.1600-0404.2009.01280.x · DOI
  11. Karalis, 2012, Use of lipid-lowering medications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patients, Cholesterol, 1, 10.1155/2012/861924 · DOI
  12. Fernandez-Hernando, 2011, MicroRNA modulation of cholesterol homeostasis, Arterioscler. Thromb. Vasc. Biol., 31, 2378, 10.1161/ATVBAHA.111.226688 · DOI · Paper page
  13. Ambros, 2004, The functions of animal microRNAs, Nature, 431, 350, 10.1038/nature02871 · DOI · Paper page
  14. Bartel, 2009, MicroRNAs: target recognition and regulatory functions, Cell, 136, 215, 10.1016/j.cell.2009.01.002 · DOI · Paper page
  15. Beekman, 2003, Evidence for a QTL on chromosome 19 influencing LDL cholesterol levels in the general population, Eur. J. Hum. Genet., 11, 845, 10.1038/sj.ejhg.5201053 · DOI
  16. Imperatore, 2000, A locus influencing total serum cholesterol on chromosome 19p: results from an autosomal genomic scan of serum lipid concentrations in Pima Indians, Arterioscler. Thromb. Vasc. Biol., 20, 2651, 10.1161/01.ATV.20.12.2651 · DOI
  17. Lewis, 2005, Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets, Cell, 120, 15, 10.1016/j.cell.2004.12.035 · DOI · Paper page
  18. Grimson, 2007, MicroRNA targeting specificity in mammals: determinants beyond seed pairing, Mol. Cell, 27, 91, 10.1016/j.molcel.2007.06.017 · DOI · Paper page
  19. John, 2004, Human microRNA targets, PLoS Biol., 2, e363, 10.1371/journal.pbio.0020363 · DOI · Paper page
  20. Alvarez, 2014, SYBR(R) Green and TaqMan(R) quantitative PCR arrays: expression profile of genes relevant to a pathway or a disease state, Methods Mol. Biol., 1182, 321, 10.1007/978-1-4939-1062-5_27 · DOI
  21. Alvarez, 2014, Faster experimental validation of microRNA targets using cold fusion cloning and a dual firefly-renilla luciferase reporter assay, Methods Mol. Biol., 1182, 227, 10.1007/978-1-4939-1062-5_21 · DOI
  22. Barad, 2004, MicroRNA expression detected by oligonucleotide microarrays: system establishment and expression profiling in human tissues, Genome Res., 14, 2486, 10.1101/gr.2845604 · DOI · Paper page
  23. Chen, 2009, MicroRNA signatures in liver diseases, World J. Gastroenterol., 15, 1665, 10.3748/wjg.15.1665 · DOI
  24. Fu, 2005, Identification of human fetal liver miRNAs by a novel method, FEBS Lett., 579, 3849, 10.1016/j.febslet.2005.05.064 · DOI
  25. Zhang, 2014, MicroRNA-27a/b regulates cellular cholesterol efflux, influx and esterification/hydrolysis in THP-1 macrophages, Atherosclerosis, 234, 54, 10.1016/j.atherosclerosis.2014.02.008 · DOI
  26. Place, 2008, MicroRNA-373 induces expression of genes with complementary promoter sequences, Proc. Natl. Acad. Sci. U. S. A., 105, 1608, 10.1073/pnas.0707594105 · DOI
  27. Esau, 2006, miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting, Cell Metab., 3, 87, 10.1016/j.cmet.2006.01.005 · DOI · Paper page
  28. Iliopoulos, 2010, MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism, J. Lipid Res., 51, 1513, 10.1194/jlr.M004812 · DOI
  29. Rayner, 2010, MiR-33 contributes to the regulation of cholesterol homeostasis, Science, 328, 1570, 10.1126/science.1189862 · DOI · Paper page
  30. Chen, 2012, The magic and mystery of microRNA-27 in atherosclerosis, Atherosclerosis, 222, 314, 10.1016/j.atherosclerosis.2012.01.020 · DOI
  31. Vickers, 2013, MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia, Hepatology, 57, 533, 10.1002/hep.25846 · DOI
  32. Choi, 2014, MicroRNA-27a modulates HCV infection in differentiated hepatocyte-like cells from adipose tissue-derived mesenchymal stem cells, PLoS One, 9, e91958, 10.1371/journal.pone.0091958 · DOI · Paper page
  33. Li, 2015, PCSK9: a key factor modulating atherosclerosis, J. Atheroscler. Thromb., 22, 221, 10.5551/jat.27615 · DOI
  34. Huang, 2012, Upregulation of cyclin B1 by miRNA and its implications in cancer, Nucleic Acids Res., 40, 1695, 10.1093/nar/gkr934 · DOI
  35. Karolina, 2012, Circulating miRNA profiles in patients with metabolic syndrome, J. Clin. Endocrinol. Metab., 97, E2271, 10.1210/jc.2012-1996 · DOI
  36. Nielsen, 2012, Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression, Exp. Diabetes Res., 2012
  37. Herrera, 2010, Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes, Diabetologia, 53, 1099, 10.1007/s00125-010-1667-2 · DOI
  38. Xie, 2009, Targeting microRNAs in obesity, Expert Opin. Ther. Targets, 10, 1227, 10.1517/14728220903190707 · DOI
  39. Alisi, 2011, Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease, Lab. Invest., 2, 283, 10.1038/labinvest.2010.166 · DOI
  40. Dowman, 2010, Pathogenesis of non-alcoholic fatty liver disease, QJM, 103, 71, 10.1093/qjmed/hcp158 · DOI
  41. Monaco, 2004, Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis, Cardiovasc. Res., 4, 671, 10.1016/j.cardiores.2003.11.038 · DOI
  42. Dubuc, 2004, Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia, Arterioscler. Thromb. Vasc. Biol., 24, 1454, 10.1161/01.ATV.0000134621.14315.43 · DOI · Paper page
  43. Lindholm, 2012, PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates, Mol. Ther., 20, 376, 10.1038/mt.2011.260 · DOI

Cited by

Sorted by citations

Metadata

Authors
Alvarez, M. L., Khosroheidari, M., Eddy, E., & Done, S. C.
Venue
Atherosclerosis
Publisher
Elsevier BV
Published
2015-10
Volume
242
Issue
2
Pages
595-604
ISSN
0021-9150
DOI
10.1016/j.atherosclerosis.2015.08.023
PMC
PMC4575910
Cited by
88
References
6
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
National Heart, Lung and Blood Institute (R01 HL093042)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review